# A Study to Evaluate the Tolerability, Safety and Efficacy of VGM-R02b

> **NCT06217861** · PHASE1 · RECRUITING · sponsor: **Shanghai Vitalgen BioPharma Co., Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- Glutaric Acidemia Type I
- Glutaric Aciduria Type I

## Interventions

- **BIOLOGICAL:** VGM-R02b

## Key facts

- **NCT ID:** NCT06217861
- **Lead sponsor:** Shanghai Vitalgen BioPharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-29
- **Primary completion:** 2027-08
- **Final completion:** 2027-08
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06217861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06217861, "A Study to Evaluate the Tolerability, Safety and Efficacy of VGM-R02b". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT06217861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*